Simone Mader

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3757678/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Annals of Neurology, 2009, 66, 630-643.	5.3	504
2	Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. Journal of Neuroinflammation, 2011, 8, 184.	7.2	379
3	Systemic Inflammation and the Brain: Novel Roles of Genetic, Molecular, and Environmental Cues as Drivers of Neurodegeneration. Frontiers in Cellular Neuroscience, 2015, 9, 28.	3.7	248
4	Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clinical Immunology, 2011, 138, 247-254.	3.2	180
5	Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease. Cells, 2019, 8, 90.	4.1	144
6	Patterns of Antibody Binding to Aquaporin-4 Isoforms in Neuromyelitis Optica. PLoS ONE, 2010, 5, e10455.	2.5	137
7	Pathogenic T cell responses against aquaporin 4. Acta Neuropathologica, 2011, 122, 21-34.	7.7	81
8	T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathologica Communications, 2013, 1, 85.	5.2	73
9	Selective Impairment of Spatial Cognition Caused by Autoantibodies to the N-Methyl-d-Aspartate Receptor. EBioMedicine, 2015, 2, 755-764.	6.1	71
10	Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta Neuropathologica, 2015, 130, 783-798.	7.7	55
11	Antibodies as Mediators of Brain Pathology. Trends in Immunology, 2015, 36, 709-724.	6.8	47
12	Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder. Arthritis and Rheumatology, 2018, 70, 277-286.	5.6	45
13	Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, 625.	6.0	44
14	Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. Current Opinion in Neurology, 2020, 33, 362-371.	3.6	44
15	The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment. Frontiers in Immunology, 2017, 8, 1101.	4.8	42
16	Features of MOG required for recognition by patients with MOG antibody-associated disorders. Brain, 2021, 144, 2375-2389.	7.6	27
17	Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. Journal of the Neurological Sciences, 2013, 328, 77-82.	0.6	22
18	Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. IScience, 2022, 25, 103659.	4.1	16

SIMONE MADER

#	Article	IF	CITATIONS
19	Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia. Multiple Sclerosis and Related Disorders, 2019, 36, 101413.	2.0	14
20	Blood-Brain Barrier Deterioration and Hippocampal Gene Expression in Polymicrobial Sepsis: An Evaluation of Endothelial MyD88 and the Vagus Nerve. PLoS ONE, 2016, 11, e0144215.	2.5	13
21	Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS. Acta Neuropathologica Communications, 2020, 8, 207.	5.2	11
22	Archeological neuroimmunology: resurrection of a pathogenic immune response from a historical case sheds light on human autoimmune encephalomyelitis and multiple sclerosis. Acta Neuropathologica, 2021, 141, 67-83.	7.7	11
23	In utero exposure to maternal anti–aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring. Science Translational Medicine, 2022, 14, eabe9726.	12.4	11
24	Mutations of Recombinant Aquaporin-4 Antibody in the Fc Domain Can Impair Complement-Dependent Cellular Cytotoxicity and Transplacental Transport. Frontiers in Immunology, 2018, 9, 1599.	4.8	4
25	Clinical significance of anti―DNA /Nâ€methylâ€Dâ€aspartate receptor 2 antibodies in de novo and postâ€steroid cases with neuropsychiatric systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2019, 22, 443-448.] 1.9	4
26	Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyond. Current Opinion in Neurology, 2022, 35, 427-435.	3.6	3
27	Serological comparison of systemic lupus erythematosus with neuropsychiatric lupus using synthetic nucleic acid antigens. Journal of Translational Autoimmunity, 2020, 3, 100068.	4.0	2